Humacyte, Inc.

HUMA

US44486Q1031

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 16/07/2024 am IST			5-day change	1st Jan Change
8.4 ^USD	+20.17%		+48.15%	+195.77%

09/07	Humacyte Signs Licensing Deal With Pluristyx For BioVascular Pancreas Product Development	MT
09/07	Pluristyx Announces License Agreement with Humacyte, Inc. to Develop BioVascular Pancreas Using iPSCs	CI

Humacyte, Inc.(NasdaqGS:HUMA) dropped from Russell Microcap Value Index

July 01, 2024

Latest news about Humacyte, Inc.

Humacyte Signs Licensing Deal With Pluristyx For BioVascular Pancreas Product Development	09/07	MT
Pluristyx Announces License Agreement with Humacyte, Inc. to Develop BioVascular Pancreas Using iPSCs	09/07	CI
Humacyte Shares Jump on FDA's Special Status Award	01/07	DJ
Humacyte's ATEV Treatment Gets New FDA Designation; Shares Rise Pre-Bell	01/07	MT
Humacyte, Inc.(NasdaqGS:HUMA) dropped from Russell Microcap Value Index	01/07	CI
Humacyte, Inc.(NasdaqGS:HUMA) dropped from Russell 3000E Value Index	01/07	CI
Humacyte, Inc.(NasdaqGS:HUMA) dropped from Russell 2000 Value Index	01/07	CI
Humacyte, Inc.(NasdaqGS:HUMA) dropped from Russell 3000 Value Index	01/07	CI
Humacyte, Inc.(NasdaqGS:HUMA) dropped from Russell 2500 Value Index	01/07	CI
Humacyte, Inc.(NasdaqGS:HUMA) dropped from Russell Small Cap Comp Value Index	01/07	CI
Humacyte, Inc. Presents Positive Preclinical Data for Its Biovascular Pancreas (Bvp??) Program	25/06	CI
Humacyte, Inc.(NasdaqGS:HUMA) added to S&P Biotechnology Select Industry Index	24/06	CI
Humacyte Insider Sold Shares Worth $4,520,024, According to a Recent SEC Filing	14/06	MT
Humacyte Insider Sold Shares Worth $4,520,024, According to a Recent SEC Filing	14/06	MT
Humacyte, Inc. Appoints Keith Anthony Jones as Class III Director	14/06	CI
Humacyte Insider Sold Shares Worth $1,561,605, According to a Recent SEC Filing	04/06	MT
Certain Common Stock of Humacyte, Inc. are subject to a Lock-Up Agreement Ending on 30-MAY-2024.	30/05	CI
Certain Warrants of Humacyte, Inc. are subject to a Lock-Up Agreement Ending on 30-MAY-2024.	30/05	CI
Certain Stock Options of Humacyte, Inc. are subject to a Lock-Up Agreement Ending on 30-MAY-2024.	30/05	CI
Transcript : Humacyte, Inc., Q1 2024 Earnings Call, May 10, 2024	10/05
Humacyte, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	10/05	CI
Transcript : Humacyte, Inc. - Special Call	28/03
Transcript : Humacyte, Inc., Q4 2023 Earnings Call, Mar 22, 2024	22/03
Interest Rate, Monetary Policy Views Lift Wall Street Pre-Bell; Asia Mixed, Europe Up	22/03	MT
Humacyte, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	22/03	CI

Humacyte, Inc. is engaged in the development and manufacturing of off-the-shelf, universally implantable, bioengineered human tissues. The Company is engaged in developing a portfolio of human acellular vessels (HAVs) with varying diameters and lengths. The HAV cabinet would initially target the vascular repair, reconstruction, and replacement market, including vascular trauma; atrioventricular (AV) access for hemodialysis; peripheral arterial disease (PAD); and coronary artery bypass grafting (CABG). The Company has developed a novel paradigm for manufacturing human tissues that are intended to mimic key aspects of human physiology. It is also engaged in developing its HAVs for pediatric heart surgery and the delivery of cellular therapies, including pancreatic islet cell transplantation to treat Type 1 diabetes. The Companyâs scientific technology platform uses primary human aortic vascular cells from a working cell stock, isolated from donor tissues and cryopreserved.

Sector

Biotechnology & Medical Research

Calendar

09/08/2024 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

8.4 USD

Average target price

9.3 USD

Spread / Average Target

+10.71%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
HUMACYTE, INC.	+195.77%	1B
MODERNA, INC.	+22.15%	46.56B
LONZA GROUP AG	+44.76%	41.67B
IQVIA HOLDINGS INC.	-2.37%	41.16B
ALNYLAM PHARMACEUTICALS, INC.	+33.84%	32.4B
ICON PUBLIC LIMITED COMPANY	+20.42%	28.18B
CELLTRION, INC.	-6.35%	28.1B
UNITED THERAPEUTICS CORPORATION	+48.83%	14.52B
MEDPACE HOLDINGS, INC.	+45.00%	13.74B
BIO-TECHNE CORPORATION	+0.06%	12.17B

Other Biotechnology & Medical Research

Humacyte, Inc.

Equities

HUMA

US44486Q1031

Biotechnology & Medical Research

Humacyte, Inc.(NasdaqGS:HUMA) dropped from Russell Microcap Value Index

Latest news about Humacyte, Inc.

Chart Humacyte, Inc.

Company Profile

Income Statement Evolution

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research